De-Cai Chen
Overview
Explore the profile of De-Cai Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma L, Chen D, Zou S, Liu Y, Zhou L, Xiu Z
Medicine (Baltimore)
. 2020 Apr;
99(15):e19753.
PMID: 32282737
Human echinococcosis has become a major public health problem in most parts of the world. The objective of this article was to study the demographics of patients with hepatic echinococcosis...
2.
Huang Y, Wang Q, Lu C, Xu Y, Cao H, Xie X, et al.
Sichuan Da Xue Xue Bao Yi Xue Ban
. 2018 Nov;
49(4):665-669.
PMID: 30378326
Objective: To determine the relationship between serum levels of 25(OH)D and 1, 25(OH) D and the hand-grip strength and balance ability of women in Sichuan, China. Methods: A cross-sectional study...
3.
Liao E, Zhang Z, Xia W, Lin H, Cheng Q, Wang L, et al.
Medicine (Baltimore)
. 2018 Aug;
97(31):e11694.
PMID: 30075569
Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to...
4.
Liao E, Zhang Z, Xia W, Lin H, Cheng Q, Wang L, et al.
BMC Musculoskelet Disord
. 2018 Jul;
19(1):210.
PMID: 29970059
Background: Vitamin D (VD) insufficiency or deficiency is a frequent comorbidity in Chinese women with postmenopausal osteoporosis (PMO). The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and...
5.
Zhou P, Xu X, Zhang Z, Liao E, Chen D, Liu J, et al.
Pharmacogenomics
. 2015 Aug;
16(10):1077-88.
PMID: 26250343
Aim: To investigate the association between SOST gene polymorphisms and response to alendronate treatment. Materials & Methods: 639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of...
6.
Gu J, Wang L, Lin H, Chen D, Tang H, Jin X, et al.
Acta Pharmacol Sin
. 2015 Jun;
36(7):841-6.
PMID: 26051110
Aim: Oral risedronate is effective in the treatment of postmenopausal osteoporosis when administered daily, weekly, or monthly. In this 1-year, randomized, double-blind, multicenter study we compared the weekly 35-mg and...
7.
Liu T, Lu C, Guo Y, Wang Q, Chen D
Sichuan Da Xue Xue Bao Yi Xue Ban
. 2014 Jun;
45(3):506-8, 528.
PMID: 24941829
Objective: To study the optimal cut-off value of phalangeal radiographic absorptiometry (RA) to identify osteoporosis in postmenopausal women. Methods: A total of 650 postmenopausal women were recruited in this study....
8.
Chen Y, Lu C, Liu T, Guo Y, Wang Q, Chen D
Sichuan Da Xue Xue Bao Yi Xue Ban
. 2013 Sep;
44(4):681-4.
PMID: 24059132
Objective: To explore the risk factors of acute-phase response (APR) following the first-dose administration of zoledronic acid in the treatment of osteoporosis. Methods: We reviewed the clinical data of the...
9.
Li M, Zhang Z, Liao E, Chen D, Liu J, Tao T, et al.
Menopause
. 2012 Sep;
20(1):72-8.
PMID: 22968256
Objective: The aim of this study was to evaluate the effect of low-dose alendronate (ALN) treatment on bone mineral density (BMD) and bone turnover markers in Chinese postmenopausal women with...
10.
Zhang J, Wang R, Zhao Y, Sun X, Zhao H, Tan L, et al.
Asian Pac J Trop Med
. 2012 Jul;
5(9):743-8.
PMID: 22805729
Objective: To compare the effect of zoledronic acid in treatment and prevention of osteoporosis with placebo. Methods: Random control trials regarding zoledronic acid in treatment of osteoporosis were retrieved by...